CVS Health Stock Outlook 2026: Can Aetna's MLR Recovery Save the Vertical Integration Thesis?

The Case For and Against CVS in 2026

CVS Health sits at a rare inflection point. The company that spent 2023–2025 absorbing massive integration costs — $10.6B for Oak Street Health, a brutal Aetna Medicare Advantage meltdown, and accelerating retail headwinds — delivered a Q1 2026 earnings beat that gave bulls their first real ammunition in 18 months.

Adjusted EPS of $2.57 beat consensus of $2.21 by 16%. Revenue hit $100.43B. Management raised full-year guidance. RBC lifted its price target to $107. On paper, the thesis is working.

But here’s the counter: CVS management also told investors that 2027 Medicare Advantage rate increases are still insufficient to cover medical cost trends. That’s not a minor footnote. It means Aetna’s profitability recovery may be more surgical and fragile than bulls want to admit.

This is the core tension in CVS stock: the vertical integration model is theoretically the most powerful structure in U.S. healthcare, but its components are all firing at different tempos. The next 12 months will determine whether this is a turnaround or a structural decline.

---

Financial Performance: Revenue Growing, Profits Collapsing

CVS’s top-line story is straightforward. Revenue has compounded from $292B in FY2021 to $402B in FY2025 — a 38% increase in four years. The problem is entirely at the margin level.

Metric	FY2021	FY2023	FY2024	FY2025
Revenue ($B)	292.1	357.8	372.8	402.1
Operating Income ($B)	13.3	13.7	8.5	4.7
Net Income ($B)	8.0	8.3	4.6	1.8
Operating Margin	4.56%	3.84%	2.28%	1.16%
EPS (diluted)	$6.02	$6.47	$3.66	$1.39
FCF/Share	$11.85	$8.06	$5.01	$6.14

The compression is not subtle. Operating margin dropped from 4.56% to 1.16% in four years while revenue grew 38%. This is the Aetna MLR problem in numerical terms: the insurance unit was paying out more in medical claims than its premium pricing assumed.

The FCF/share figure ($6.14 in FY2025, recovering from $5.01 in FY2024) shows the underlying cash generation capacity is still intact — and why dividend sustainability is better than the GAAP EPS picture suggests.

---

Four Segments, Four Stories

Health Care Benefits (Aetna) is the problem and the opportunity. Aetna’s commercial insurance, Medicare Advantage, and Medicaid products generated roughly $132B in revenue but ran into an MLR crisis when post-COVID utilization patterns — more elective surgeries, higher specialist visits — overshot actuarial assumptions. The Q1 2026 signal is the first credible evidence of improvement.

Health Services (Caremark + Oak Street + MinuteClinic) is CVS’s largest and most strategically interesting segment. Caremark, the pharmacy benefit manager, processes hundreds of millions of prescriptions annually and competes with Express Scripts (Cigna) and OptumRx (UnitedHealth). Oak Street Health, added in 2023, provides the primary care layer. MinuteClinic offers acute care clinics inside CVS stores.

Pharmacy & Consumer Wellness is the retail segment most Americans think of when they think of CVS — the corner drugstore. Growth has been muted, and the 900-store closure plan acknowledges that physical retail is not the growth engine. Generic drug dispensing and specialty pharmacy are the margin drivers.

Corporate handles shared services and debt management. With substantial leverage from recent acquisitions, interest expense is a meaningful drag.

---

Oak Street Health: The $10.6B Bet on Value-Based Care

Value-based primary care is the most structurally interesting concept in U.S. healthcare — and Oak Street is CVS’s wager on it. The model: instead of billing fee-for-service, Oak Street accepts a fixed per-member-per-month payment from Medicare and manages the patient’s total health. Every hospitalization avoided translates directly into profit.

CVS’s integration thesis is clear: Aetna MA members directed to Oak Street clinics → fewer hospitalizations → lower medical claims → Aetna MLR improvement. Caremark’s prescription data feeds Oak Street’s clinical decision-making. CVS pharmacies handle the medication component.

The math, when it works, is extraordinary. Mature Oak Street clinics reportedly generate strong unit economics. The challenge is that new clinic openings require 2–3 years of investment before reaching full patient panel capacity. CVS acquired 600+ clinic locations still in various stages of maturity.

Oak Street is not yet profitable at the corporate level. Its losses were a meaningful contributor to the FY2025 operating income collapse. The trajectory into 2026–2027 — specifically, how quickly Oak Street’s aggregate clinic portfolio moves to EBITDA breakeven — is arguably the most important variable in CVS’s earnings model. See our JNJ stock analysis for a comparison of how large healthcare acquirers manage integration timelines.

---

Caremark PBM: Between Monopoly Profit and Regulatory Fire

Caremark, Express Scripts, and OptumRx collectively process roughly 80% of U.S. retail prescriptions. This concentration has made PBMs the primary target of healthcare cost-control legislation in both chambers of Congress and at the FTC.

The core criticism: PBMs extract rebates from drug manufacturers as a condition of formulary placement, keep a portion as profit rather than passing savings to plan sponsors, and then reimburse independent pharmacies at rates that are often below cost. The result, critics argue, is a system that inflates drug costs while consolidating market power.

For CVS, PBM regulatory risk is real but timing is uncertain. Legislation has been “imminent” for three years without passing. A 10–15% haircut to Caremark operating income is the plausible downside if meaningful reform passes.

On the GLP-1 front — Ozempic, Wegovy, Mounjaro — CVS sits in an awkward position. More prescriptions mean more Caremark revenue, but more Aetna claims means higher MLR. Cost management through formulary tiering and prior authorization is Caremark’s lever. See our GLP-1 insurance coverage guide for details on how insurers are navigating this.

---

Medicare Advantage Star Ratings: The October 2026 Catalyst

CMS assigns star ratings (1–5 stars) to Medicare Advantage plans annually, and plans rated 4 stars or above receive quality bonus payments worth billions across the industry. Aetna plans that slipped below 4 stars in recent cycles contributed to the revenue shortfall that compounded the MLR problem.

October 2026 star rating announcements determine 2027 MA revenues. This makes October 2026 the single most important catalyst date in CVS’s near-term calendar. A broad recovery to 4-star status would not only restore bonus payments but also allow more aggressive MA marketing (CMS restricts marketing for low-rated plans) and reduce member churn.

CVS management has named star rating recovery as a top organizational priority for 2026. Achieving it requires sustained improvement in quality metrics — member satisfaction scores, care gap closures, medication adherence rates — metrics that Oak Street’s model is specifically designed to improve.

---

Competitive Landscape: UNH, ELV, Cigna

For sector context, see our UNH stock outlook and ELV stock outlook.

Metric	CVS	UNH	ELV	CI
Market Cap	~$111B	~$250B+	~$90B	~$80B
Forward P/E	~11.5x	~18x	~12x	~13x
Dividend Yield	3.1%	1.8%	1.5%	1.6%
Vertical Integration	Maximum	High	Moderate	Moderate
MA Exposure	High	Very High	Moderate	Low

CVS commands the lowest valuation multiple in the group — justified by execution risk but also the source of upside if MLR normalizes. UnitedHealth carries its own headline risks following the Change Healthcare cyberattack and subsequent events. Elevance is more Medicaid-heavy, creating state budget sensitivity. Cigna has largely pivoted to Evernorth (its PBM/pharmacy unit), reducing insurance exposure.

---

Bull / Base / Bear: 12-Month Price Targets

Bull Case — $115 (+32%)

Aetna MLR drops visibly by Q2–Q3 2026. Oak Street posts first EBITDA-positive quarter. October 2026 star ratings show broad 4-star recovery. PBM legislation stalls in Congress. Adjusted EPS recovers toward $10+ and multiple expands to 11.5x → implied $115.

Base Case — $95–$105 (+9–20%)

MLR improvement is gradual, visible in H2 2026. Oak Street EBITDA turns positive in 2027. Partial star rating recovery. PBM oversight intensifies but no legislation passes. Adjusted EPS of $8–$9, dividend maintained. Convergence to consensus $96.89.

Bear Case — $65–$75 (-14–25%)

MLR improvement proves illusory in Q2. CMS 2027 rate announcement is unfavorable. PBM legislation advances. Dividend cut. Multiple compresses to 8x on $8 adjusted EPS → $64.

---

Investment Conclusion

CVS is not a broken company — it is a vertically integrated healthcare conglomerate in the middle of the most complex integration in its history, with the results still genuinely ambiguous. The forward P/E at 11.5x prices in significant skepticism. The Q1 2026 beat and guidance raise are the first data points in what needs to be a consistent series of MLR improvement confirmations.

The right approach for most investors: initiate or add at current levels with a clear exit trigger (MLR reacceleration or MA star rating collapse), and use Q2 2026 earnings as the next evidence checkpoint. CVS’s vertical integration thesis is finally being tested at scale — 2026 is when investors will learn whether the model works.